Amantadine

Overview

Amantadine is an antiviral drug with N-methyl-D-aspartate (NMDA) receptor antagonist activity that is used extra-label in small animal medicine. In dogs and cats, its primary clinical role is as an adjunctive medication for the management of chronic and neuropathic pain rather than for antiviral purposes.

Amantadine is generally not effective when used alone for pain control. Instead, it is most commonly incorporated into multimodal analgesic protocols alongside other agents such as NSAIDs, opioids, or gabapentin-based therapies, particularly in patients with persistent pain that is poorly responsive to conventional analgesics.

The analgesic benefit of amantadine is related to its ability to modulate central sensitization within the nervous system. Clinical improvement may be gradual, and several weeks of therapy may be required before a noticeable reduction in chronic pain intensity is achieved.

Indications

In dogs and cats, amantadine is used primarily as an adjunctive analgesic rather than as an antiviral agent. Its clinical use focuses on modulation of chronic pain states that are inadequately controlled with conventional therapies alone.

• Adjunctive treatment of chronic pain: Used in dogs and cats with chronic pain conditions, particularly when response to opioids alone is insufficient or higher opioid doses are poorly tolerated.
• Neuropathic pain: Incorporated into multimodal analgesic protocols to help manage neuropathic pain by reducing central sensitization and NMDA receptor–mediated pain amplification.
• Prevention of pain “wind-up”: Used to help interrupt or prevent central sensitization (“wind-up”) in patients with persistent or long-standing pain.

Dosage (Reference)

Dog

In dogs, amantadine is used extra-label as an adjunctive analgesic for chronic and neuropathic pain. It should not be used as a sole analgesic and is most effective when incorporated into a multimodal pain management protocol.

Cat

In cats, amantadine is used extra-label as part of multimodal analgesic protocols for chronic or neuropathic pain. Published clinical experience in cats is limited, and careful dose titration is recommended.

Warnings & Precautions

Amantadine should be used cautiously in dogs and cats due to its effects on the central nervous system and its primary renal elimination. Limited veterinary data are available, and careful patient selection and monitoring are essential.

• Renal disease: Amantadine is primarily eliminated by the kidneys; dose adjustment or increased monitoring may be required in dogs and cats with renal impairment.
• Seizure disorders: Use with caution in patients with a history of seizures, as amantadine may lower the seizure threshold.
• Behavioral effects: Dogs may exhibit agitation, anxiety, or restlessness, particularly during the early phase of treatment.
• Gastrointestinal effects: Flatulence, loose stools, or diarrhea may occur; these effects are often transient but should be monitored.
• Limited feline data: Clinical experience in cats is limited; adverse effects may be more common or less predictable than in dogs.
• Cardiac and neurologic disease: Use cautiously in patients with underlying cardiac disease or neurologic conditions due to potential CNS stimulation.
• Drug name confusion: Care should be taken to avoid medication errors; amantadine should not be confused with similarly named drugs.

Drug Interactions

Amantadine has several clinically relevant drug interactions, primarily related to additive central nervous system effects, anticholinergic activity, or altered renal excretion. Careful consideration and monitoring are required when combining amantadine with other medications in dogs and cats.

• Anticholinergic drugs (e.g., atropine, glycopyrrolate, oxybutynin):
  Concurrent use may enhance anticholinergic effects, increasing the risk of dry mouth, ileus, agitation, or urinary retention.
• Antihistamines (e.g., diphenhydramine, hydroxyzine):
  May potentiate anticholinergic and sedative effects when used with amantadine.
• CNS stimulants (e.g., caffeine, selegiline, methylphenidate):
  Concomitant use may increase CNS stimulation, anxiety, restlessness, or agitation.
• Phenothiazines (e.g., acepromazine):
  May enhance anticholinergic effects and increase the risk of neurologic adverse effects.
• Tramadol:
  Concurrent use may increase the risk of seizures due to additive effects on lowering the seizure threshold; monitor closely for neurologic signs.
• Quinidine or quinine:
  May reduce renal clearance of amantadine, leading to increased plasma concentrations.
• QT-prolonging drugs (e.g., amiodarone, cisapride, procainamide, sotalol):
  Concurrent use may increase the risk of cardiac arrhythmias; avoid combination when possible.
• Sulfonamides / trimethoprim:
  May decrease amantadine excretion and increase systemic exposure.
• Tricyclic antidepressants (e.g., amitriptyline, clomipramine):
  May enhance anticholinergic and CNS effects.
• Urinary acidifiers (e.g., methionine, ammonium chloride, ascorbic acid):
  May increase renal excretion of amantadine and reduce drug concentrations.
• Urinary alkalinizers (e.g., sodium bicarbonate, potassium citrate):
  May decrease renal excretion of amantadine, increasing the risk of toxicity.

Side Effects & Overdose

Side Effects

Experience with amantadine in dogs and cats is limited, and the adverse effect profile is not fully characterized. Reported adverse effects are primarily related to gastrointestinal and central nervous system stimulation.

• Gastrointestinal effects: Flatulence, loose stools, or diarrhea may occur, particularly during the early stages of treatment.
• Behavioral changes (dogs): Agitation, anxiety, or restlessness have been reported, especially shortly after initiation of therapy.
• Cats: Published adverse effect data are limited; some clinicians report gastrointestinal effects may be more common than in dogs.

Overdose

Amantadine overdoses can be serious in dogs and cats due to its effects on the central nervous system and cardiovascular system. There is no specific antidote for amantadine toxicity.

• Toxic doses: Behavioral effects may be seen at doses around 15 mg/kg in dogs and cats; a toxic dose of approximately 30 mg/kg has been reported in cats.
• Clinical signs (dogs): Tremors, anxiety, ataxia, hypersalivation, and vomiting have been reported.
• Central nervous system toxicity: Severe cases may progress to seizures, marked agitation, or altered mental status.
• Management: Treatment is supportive and may include gastrointestinal decontamination when appropriate, intensive monitoring, and symptomatic care.
• Consultation: In suspected overdose cases, consultation with a veterinary poison control center is strongly recommended.

Key Notes

Practical clinical considerations to optimize the safe and effective use of amantadine in dogs and cats:

• Adjunctive role: Amantadine should be viewed as a co-analgesic rather than a primary pain medication and is most effective when integrated into a multimodal pain management plan.
• Delayed benefit: Clinical improvement is often gradual; lack of immediate response does not indicate treatment failure.
• Central sensitization: The drug is particularly useful in patients with established central sensitization, where traditional analgesics alone provide inadequate relief.
• Individual variability: Response to amantadine varies widely among patients; dosing intervals and overall benefit should be tailored to the individual animal.
• Compounding considerations: Accurate dosing may require compounding, especially for small patients, to reduce the risk of dosing errors.
• Client communication: Owners should be advised that this medication is intended to improve comfort over time and must be administered consistently as prescribed.